The Pharmacy Times® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.
June 30th 2025
Across 3 different manufacturing lots, V116 (21-valent pneumococcal conjugate vaccine) demonstrated consistent immunogenicity and efficacy against S pneumoniae, which causes pneumococcal diseases.
Pneumococcal Disease Prevention for Older Adults and the Pharmacist’s Role in an Evolving Vaccine Landscape
1.0 Credit / Immunization, Infectious Diseases
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
The Role of the Pharmacist in Influenza Prevention for At-Risk Adults: Strategies to Enhance Immunization
1.5 Credits / Infectious Diseases
View More
The Essential Role of Pharmacists in Improving Influenza Vaccination Coverage: Strategies to Increase Vaccine ...
1.0 Credit / Immunization, Infectious Diseases
View More
The Role of Pharmacists in Pneumococcal Prevention: Strategies to Improve Vaccine Uptake
1.0 Credit / Immunization, Infectious Diseases, Pulmonology
View More
Insights in Influenza Immunization: The Long-Term Care Pharmacist’s Role in Improving Health Outcomes in At-Ri...
1.0 Credit / Immunization, Infectious Diseases
View More
Exploring HIV Long-Acting Injectable Uptake: How Pharmacists Can Encourage Long-Acting Injectables to Stem the...
1.5 Credits / HIV/AIDS, Infectious Disease
View More
Beyond the Spots: Management of Measles
1.0 Credit / Infectious Disease, Immunization
View More
Optimizing the Uptake of Long-Acting Injectables in HIV Treatment and Prevention: Considerations for Managed C...
1.5 Credits / HIV/AIDS, Infectious Disease
View More
Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage
1.5 Credits / Immunization, Infectious Disease, Pulmonology
View More
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
0.75 Credit / Oncology, Law
View More
Targeted Screening Tools Can Increase Pneumococcal Vaccine Uptake in Health System Retail Pharmacies
June 5th 2025Implementation of the Plan-Do-Study-Act cycle in health system retail pharmacies significantly increased uptake of 20-valent pneumococcal conjugate vaccine among eligible adults.
Read More
PCV10 Elicits Durable Immune Response in T2D, Though Response Remains Inferior to Nondiabetics
April 19th 2025These results suggest that individuals who are immunocompromised with type 2 diabetes (T2D) may need multiple doses of a pneumococcal conjugate vaccine (PCV) to sustain their protection.
Read More
Two Biomarkers Improve CRB-65 Predictability for Death Due to Community-Acquired Pneumonia
December 16th 2024The study authors add that the validation improved the risk score in additional community-acquired pneumonia cohorts, and clinical studies would assess the broad clinical applicability.
Read More
Childhood Pneumococcal Vaccination Programs Indirectly Protect Adults From Pneumococcal Disease
November 29th 2024Pneumococcal disease incidence decreased in adults after pneumococcal vaccines began to be used in children due to indirect protection, with fewer adults found to carry the bacterium that causes disease.
Read More
Clinical Considerations for Pneumococcal Vaccination Scheduling
The medical experts explore the importance of receiving PCV20 following PCV13 and PPSV23 vaccinations, while also delving into the broader discussion of how sequential administration of these pneumococcal vaccines may potentially enhance protection against targeted strains.
Watch
ACIP Recommendations for Pneumococcal Vaccination
The panel of experts examines the most recent ACIP recommendations for pneumococcal vaccination in adults aged 65 and older, highlighting key updates and changes to the guidelines.
Watch
Target Patient Populations for Pneumococcal Vaccines
Krista D. Capehart, PharmD, BCACP, FAPhA, Dr. Capeheart outlines the patient populations for whom pneumococcal vaccines are indicated and provides a detailed explanation of the ACIP-recommended immunization schedules for these vaccines.
Watch
Comparing and Contrasting the Characteristics of the FDA-Approved Pneumococcal Vaccines
The pneumococcal vaccination experts offer a comparative analysis of the five FDA-approved pneumococcal vaccines, focusing on their structural differences and the specific strains each vaccine targets.
Watch